Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT +24.39%12 EV-to-EBITDA is -492.48 as of Aug. 03, 2026. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 3 warning signs investors should review. Among 416 Biotechnology companies, SL Science Holding ranks worse than 240384.38% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, SL Science Holding's enterprise value is $1,843.85 Mil.
SL Science Holding's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.74 Mil. Therefore, SL Science Holding's EV-to-EBITDA for today is -492.48.
The historical rank and industry rank for SL Science Holding's EV-to-EBITDA or its related term are showing as below:
SLBT'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -896.88 Med: -643.76 Max: -390.63
Current: -492.48
During the past 3 years, the highest EV-to-EBITDA of SL Science Holding was -390.63. The lowest was -896.88. And the median was -643.76.
SLBT's EV-to-EBITDA is ranked worse than 100% of 416
companies
in the Biotechnology industry
Industry Median: 11.9
vs SLBT: -492.48
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
SL Science Holding's PE Ratio (TTM) for today is calculated as:
SL Science Holding's share price for today is $3.29.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SL Science Holding's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.007.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for SL Science Holding's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding EV-to-EBITDA Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
EV-to-EBITDA
0.00
0.00
0.00
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
EV-to-EBITDA
0.00
0.00
0.00
0.00
0.00
SLBT vs DMRA, BCAX, TYRA: EV-to-EBITDA Comparison
For the Biotechnology subindustry, SL Science Holding's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where SL Science Holding's EV-to-EBITDA falls into.
SL Science Holding's current Enterprise Value is $1,843.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SL Science Holding's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $-3.74 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding (SLBT) has a EV-to-EBITDA of -492.48 as of Aug. 03, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SL Science Holding. According to the industry distribution chart, SL Science Holding ranks #999999 out of 416 companies in the Biotechnology industry.
Is SL Science Holding's EV-to-EBITDA too high?
SL Science Holding's current EV-to-EBITDA is -492.48. Based on the distribution chart, SL Science Holding ranks #999999 out of 416 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's EV-to-EBITDA compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #999999 out of 416 companies for EV-to-EBITDA. This places SL Science Holding in the lower half of its industry. The industry median EV-to-EBITDA is 11.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.90, based on 416 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on SL Science Holding. For the Biotechnology industry, the median EV-to-EBITDA is 11.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SL Science Holding's current EV-to-EBITDA is -492.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current EV-to-EBITDA of -492.48. The current EV-to-EBITDA is -492.48. SL Science Holding's overall GF Score™ is 12/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For SL Science Holding (SLBT), the current EV-to-EBITDA is -492.48 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
